Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ELC200 · 4 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| ELC200 (carbidopa+levodopa+entacapone) | DRUG | - |
Inclusion Criteria: * Healthy male and female subjects age 18 to 55 years of age included, and in good health * At Screening, and Baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed after the subject has rested for at least five (5) minutes, and again when ...
ELC200 is an investigational small molecule developed by Novartis AG. It is a fixed-dose combination of carbidopa, levodopa, and entacapone. The program has been studied in Phase 1 bioequivalence trials in healthy volunteers in Germany, with four completed studies and 168 total participants enrolled.
ELC200 is developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 1 bioequivalence studies of the carbidopa, levodopa, and entacapone combination conducted in Germany.
ELC200 is in Phase 1 development. Four Phase 1 bioequivalence trials have been completed, and no trials are currently active. The studies enrolled 168 participants in total and were conducted in healthy volunteers in Germany.
ELC200 has been evaluated in four completed Phase 1 bioequivalence trials: NCT00415922, NCT00415844, NCT00415831, and NCT00415740. Each enrolled 42 healthy volunteers in Germany and compared the carbidopa, levodopa, and entacapone combination against carbidopa/levodopa plus entacapone.
ELC200 is an investigational fixed-dose combination of carbidopa, levodopa, and entacapone. Its clinical program consists of Phase 1 bioequivalence studies in healthy volunteers rather than patient populations, so the trials evaluated drug exposure comparisons rather than treatment outcomes in a specific disease.